OSENVELT
Osenvelt (denosumab-bmwo) is a RANK ligand inhibitor indicated for the prevention of skeletal-related events in patients with multiple myeloma and those with bone metastases from solid tumors. It is also approved for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgery would result in severe morbidity. Additionally, the drug is used to treat hypercalcemia of malignancy in patients whose condition is refractory to bisphosphonate therapy. This therapeutic agent serves to manage bone pathology and calcium release associated with specific oncological conditions.
How OSENVELT Works
Osenvelt binds to RANKL, a protein essential for the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By preventing RANKL from activating its receptor (RANK) on the surface of osteoclasts and their precursors, the drug inhibits bone breakdown and the resulting release of calcium. In giant cell tumors of bone, this process interferes with the signaling that contributes to osteolysis and tumor growth. This mechanism modulates bone pathology in instances where increased osteoclast activity is stimulated by solid tumors or osseous metastases.
Details
- Status
- Prescription
- First Approved
- 2025-02-28
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
OSENVELT Approval History
What OSENVELT Treats
4 indicationsOSENVELT is approved for 4 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Myeloma
- Bone Metastasis
- Giant Cell Tumor of Bone
- Hypercalcemia of Malignancy
Pharmacists can substitute OSENVELT for Prolia without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
Drugs Similar to OSENVELT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OSENVELT FDA Label Details
ProIndications & Usage
FDA Label (PDF)Osenvelt is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Osenvelt is indicated for the prevention of skeletal-related events in patients with multiple myeloma...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.